However, antibody therapy has limited bio-distribution and its benefits may be short-lived, so it is imperative to explore other approaches employing single or combination treatments with brentuximab vedotin to improve its anti-tumor activity for r/r CD30+ lymphoma patients. The gene discussed is TNFRSF8; the disease is neoplasm.